[go: up one dir, main page]

WO2014141298A3 - Composition pharmaceutique stable de fingolimod - Google Patents

Composition pharmaceutique stable de fingolimod Download PDF

Info

Publication number
WO2014141298A3
WO2014141298A3 PCT/IN2014/000153 IN2014000153W WO2014141298A3 WO 2014141298 A3 WO2014141298 A3 WO 2014141298A3 IN 2014000153 W IN2014000153 W IN 2014000153W WO 2014141298 A3 WO2014141298 A3 WO 2014141298A3
Authority
WO
WIPO (PCT)
Prior art keywords
fingolimod
pharmaceutical composition
stable pharmaceutical
present
bioequivalent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2014/000153
Other languages
English (en)
Other versions
WO2014141298A2 (fr
Inventor
Kapil AGNIHOTRI
Balvir SINGH
Ashish Sehgal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astron Research Ltd
Original Assignee
Astron Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astron Research Ltd filed Critical Astron Research Ltd
Publication of WO2014141298A2 publication Critical patent/WO2014141298A2/fr
Publication of WO2014141298A3 publication Critical patent/WO2014141298A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition pharmaceutique stable de fingolimod ou ses sels pharmaceutiquement acceptables, et son procédé de préparation. Les compositions pharmaceutiques de la présente invention peuvent être dispensées sous forme dosifiée orale, et constituent des bioéquivalents du produit commercialisé Fingolimod.
PCT/IN2014/000153 2013-03-11 2014-03-10 Composition pharmaceutique stable de fingolimod Ceased WO2014141298A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN725/MUM/2013 2013-03-11
IN725MU2013 2013-03-11

Publications (2)

Publication Number Publication Date
WO2014141298A2 WO2014141298A2 (fr) 2014-09-18
WO2014141298A3 true WO2014141298A3 (fr) 2014-12-24

Family

ID=51538248

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2014/000153 Ceased WO2014141298A2 (fr) 2013-03-11 2014-03-10 Composition pharmaceutique stable de fingolimod

Country Status (1)

Country Link
WO (1) WO2014141298A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089341A1 (fr) * 2003-04-08 2004-10-21 Novartis Ag Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre
WO2009048993A2 (fr) * 2007-10-12 2009-04-16 Novartis Ag Compositions comprenant des modulateurs du récepteur de sphingosine 1-phosphate (s1p)
US20100040678A1 (en) * 2006-09-26 2010-02-18 Michael Ambuhl Organic compounds
WO2012135561A1 (fr) * 2011-04-01 2012-10-04 Novartis Ag Formulations comprenant 2-amino-2-[2-(4-octylphényl)éthyl]propane-1,3-diol

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089341A1 (fr) * 2003-04-08 2004-10-21 Novartis Ag Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre
US20100040678A1 (en) * 2006-09-26 2010-02-18 Michael Ambuhl Organic compounds
WO2009048993A2 (fr) * 2007-10-12 2009-04-16 Novartis Ag Compositions comprenant des modulateurs du récepteur de sphingosine 1-phosphate (s1p)
WO2012135561A1 (fr) * 2011-04-01 2012-10-04 Novartis Ag Formulations comprenant 2-amino-2-[2-(4-octylphényl)éthyl]propane-1,3-diol

Also Published As

Publication number Publication date
WO2014141298A2 (fr) 2014-09-18

Similar Documents

Publication Publication Date Title
WO2012021715A3 (fr) Formulations stables de linaclotide
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
NZ709958A (en) Enhanced stability of novel liquid compositions
WO2013188273A8 (fr) Composition pharmaceutique ophtalmique topique contenant de l'axitinib
WO2013188268A8 (fr) Composition pharmaceutique ophtalmique topique contenant du pazopanib
WO2014203275A3 (fr) Procédé amélioré pour la préparation d'apixaban et de ses intermédiaires
WO2014033526A9 (fr) Compositions pharmaceutiques d'étoricoxib
IL227024A (en) The 3 heteroarylamino propionic acid derivatives are converted into amino acids, a process for their preparation, their use in the preparation of medicinal preparations and as medical preparations containing them
MX2016001422A (es) Composicion farmaceutica de fingolimod.
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
IL262494A (en) A pharmaceutical combination preparation containing Ivacaptor and Lomaceptor complex compositions, their salts and derivatives, a process for their preparation and pharmaceutical preparations containing them
WO2014166836A8 (fr) Formulation de composés d'hormone de croissance
WO2014125504A3 (fr) Compositions pharmaceutiques de fébuxostat
WO2013188279A8 (fr) Composition pharmaceutique ophtalmique topique contenant du cediranib
GR1008228B (el) Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου
WO2016197042A8 (fr) Formulations à libération modifiée ou ciblée de linaclotide
MX370184B (es) Composición farmacéutica que comprende fingolimod.
WO2014122671A3 (fr) Compositions orales solides de saxagliptine
WO2014141298A3 (fr) Composition pharmaceutique stable de fingolimod
WO2012153347A3 (fr) Composition pharmaceutique d'olanzapine de forme 1 à administration par voie orale
WO2012060791A3 (fr) Procédé de production de compositions pharmaceutiques comprenant du cefdinir
WO2012120541A3 (fr) Forme amorphe d'un mélange de lopinavir et de ritonavir
IN2013MU03123A (fr)

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 14764027

Country of ref document: EP

Kind code of ref document: A2